why choose us

First received: August 12, 2022

Clinical Trial: Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Lymphoblastic Leukemia

Study Type: INTERVENTIONAL


Official Title: Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Brief Summary: Acute lymphoblastic leukemia (ALL) is the most common cancer seen in pediatric oncology.The necessary chemotherapy for pediatric and adolescent and young adult (AYA) patients with ALL includes steroids, anthracyclines, asparaginase, and vincristine.One of the most hepatotoxic chemotherapy agents is asparaginase, with treatment-associated hepatotoxicity (TAH) observed in up to 60% of patients.The frequency of TAH is increased in overweight or obese patients of Latino heritage.Carnitine is a naturally-derived…

Read more